Fluorescein Sodium
Sponsors
Assistance Publique Hopitaux De Paris, Rophibio Inc., Indiana University, AdventHealth, UpTru Inc.
Conditions
Adult Intracranial NeoplasmCerebrovascular DisordersExtramammary Paget's DiseaseHead and NeckHead and Neck DisorderIntracranial NeoplasmsNeovascular age-related macular degeneration (nAMD)Pleomorphic Adenoma of the Parotid
Phase 1
Phase 2
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
CompletedNCT04351373
Start: 2021-10-06End: 2022-05-25Updated: 2023-08-01
Identification of Nerves Using Fluorescein Sodium
Enrolling by invitationNCT06054178
Start: 2024-11-07End: 2025-09-01Target: 30Updated: 2025-07-28
A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)
RecruitingNCT06873815
Start: 2025-03-07End: 2027-03-31Target: 27Updated: 2026-01-12
Phase 3
Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent non-infectious uveitis. FOCUS: treatment FOr Corticosteroid dependent UveitiS
RecruitingCTIS2023-505112-38-00
Start: 2024-07-01Target: 120Updated: 2025-04-22
A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
CompletedCTIS2023-509206-29-00
End: 2025-04-17Target: 289Updated: 2025-02-24
Phase 4
Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions
TerminatedNCT02028325
Start: 2013-12-31End: 2016-10-31Updated: 2016-11-08
Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions
NCT02478346
Start: 2015-05-31End: 2019-04-30Target: 200Updated: 2017-02-14
Dose Optimization for Safe and Efficient Fluorescein Angiography (DOSE Study)
CompletedNCT05664555
Start: 2023-02-01End: 2024-03-31Updated: 2024-04-17